Phenotyping

Our mission is to give you a ready access to high-quality animal models for your next research program. Clinical phenotyping services address most of the physiological systems and cover most of the therapeutic areas, by using genetically engineered mouse models, spontaneous or induced pathological models.

Our services enable to characterize the anatomical, physiological and behavioral phenotype traits of your mouse model, as well as validate target genes, assess your mouse model to mimic a specific human disease or perform in vivo preclinical drug screening.

8 Platforms services:

  • 150-200 projects per year
  • 12 therapeutic areas
  • In vivo disease models
  • More than 250 standardized assays for various functions
  • Broad range R&D programs

Clinical phenotyping

 

 

 

DISEASE MODELS
  • Lung disease
  • Asthma
  • Lung inflammation
  • Intestinal bowel disease (~DSS)
  • Peritonitis (LPS, Thyoglycolate, poly:IC, Zymosan A)
  • Hypertension
  • Cardiac hypertrophy
  • Diet-induced atherosclerosis
  • Diet-induced obesity
  • Diet-induced Diabetes
  • Memory and learning deficits
  • Alzheimer
  • Orthotopic cancer models
  • Design vaccine assays
  • Immunisation modes (TNP-KLH)
  • EAE-Experimental autoimmune encephalomyelitis

Drug screening

  • Target identification/ validation
  • Risk assessments / side effects
  • Target reorientation

Bio-imaging under BSL3 conditions

  • Biphotonic in vivo imaging
  • Confocal imaging
  • Bioluminescence
  • Cryomicrotome

Preclinical imaging

  • Optical imaging
    • Bioluminescence and planar fluorescence
    • Fluorescence tomography
  • X-Ray imaging
    • Planar radiology
    • Micro Computed tomography
  • Radioisotopic imaging
    • Planar scintigraphy
    • Single photonemission computed tomography (SPECT)
    • Positron Emission Tomography (PET)
  • Photoacoustic imaging
  • Ultrasounds imaging

We provide researchers with phenotyping tools, define together with the teams the most suited strategies to address their scientific questions and provide targeted and comprehensive analysis. PHENOMIN services are regularly renewed and implemented thanks to R&D programs addressed in different clinical phenotyping areas and disease models.


In vivo Imaging
A great variety of complementary imaging modalities

PHENOMIN provides a great variety of complementary imaging modalities.

Thanks to dramatic advances in equipment, detectors and imaging probes, there has been an increasing availability of in vivo imaging modalities to detect biological processes in preclinical models, especially in mice and rats, with great sensitivity and high resolution. One of the main advantages of in vivo imaging is the possibility to monitor repetitively and non invasively the evolution of a phenomenon in the same animal, over time. Imaging sets up as a unique tool for translational research and exhibit a high potential to accelerate the understanding of disease and help to select drug candidates for pharmaceutical development.

Anatomical imaging

  • X-Ray imaging
    • Bone structure, bone mineral density (DEXA analysis)
    • Lung (with respiratory gating)
    • X-ray guided imaging
    • Oncology
    EQUIPMENT
    • Faxitron and flat panel
    • Computed Tomograph CT120
    • Computed Tomograph Quantum FX
  • Ultrasounds imaging
    • Analysis of blood flow, organ and tumor vasculature
    • Anatomical imaging, cancer biology, embryology and reproduction, cardiology, vascular system, nephrology, hepatology, ophthalmology, rheumatology, regenerative medicine and stem cells
    • Ultrasound-guided injection and biopsy
    • Contrast imaging (microbubbles)
    EQUIPMENT
    • Vevo 2100

R&D program: Embryos imaging by ECT

Functional and/or molecular imaging

  • Radioisotopic imaging (SPECT, PET)
    EQUIPMENT
    • Gamma imager
    • NanoSPECT/CT
    • eXplore Vista PET
    • Bone metabolism, lung aloveolocapilary integrity, liver (hepatocytic function, biliary function, gallbladder ejection, phagocytosis), intestine (gastric emptying and first segment intestine motility)
    • Cancer (tumor metabolism, targeting by labeled monoclonal antibody)
    • Imaging of macrophages, granulocytes phagocytosis and recruitment by lesions
    • Biodistribution studies

    R&D program: apoptosis, hypoxia

  • Optical imaging (bioluminescence, fluorescence, two-photon microscopy)
    EQUIPMENT
    • Ivis Lumina
    • Ivis Lumina II
    • BioFLECT
    • Two photon
    • Oncology (bioluminescent tumor cell lines or fluorescent probes): proliferation, metastasis, drug efficacy
    • In vivo and in situ visualization of the spread of infection
    • Infection (bioluminescent bacteria)
    • In vivo imaging in BSL3 conditions
    • Gene expression

    R&D program: apoptosis

  • Photoacoustic (coupled to ultrasounds)
    EQUIPMENT
    • Vevo LAZR
    • Lymphatic system including lymphangiogenesis
    • Skin (melanoma, cutaneous tumor, aging)
    • Molecular imaging, Nanoparticles biodistribution and targeting
    • Hypoxia

    R&D program: microbiodistribution in tumors

We provide researchers with innovative imaging tools and define, together with the teams, the most suited imaging strategies to address their scientific issues.